A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
National Cancer Institute (NCI)
Pfizer
Trishula Therapeutics, Inc.
Coherus Oncology, Inc.
Canadian Cancer Trials Group
Celgene
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Northwestern University
Radiation Therapy Oncology Group
Amgen
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)